Cantargia AB (CANTA) Price & Analysis

Compare

3 Followers

CANTA Stock Chart & Stats

kr4.10

-kr0.02(-1.25%)

At close: Mar 06 4:00 PM EST

kr4.10

-kr0.02(-1.25%)

Day’s Range― - ―

52-Week Rangekr1.00 - kr6.59

Previous CloseN/A

Volume611.88K

Average Volume (3M)1.42M

Market Cap

kr986.99M

Enterprise Valuekr705.17M

Total Cash (Recent Filing)kr281.82M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)7.1

Beta0.74

Next Earnings

May 26, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding248,611,650

10 Day Avg. Volume1,074,033

30 Day Avg. Volume1,417,172

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)3.91

Price to Sales (P/S)3.28

P/FCF Ratio6.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr13.99

Price Target Upside241.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.64

Revenue Forecast (FY)kr2.93M

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementAnalyst notes nadunolimab is positioned for a pivotal pancreatic cancer study, with regulatory approval and financing milestones able to serve as significant catalysts for the stock.

Diagnostic-driven Patient SelectionAnalyst highlights a planned IL1RAP-based companion diagnostic to identify patients most likely to respond, which could improve trial efficiency and increase observed response rates.

Strategic Partnership And FundingAnalyst points out that the CAN10 acquisition by a large pharmaceutical company validates the IL1RAP approach and provided non-dilutive funding that frees resources for other pipeline programs.

Bears Say

Trial Population ResistanceAnalyst cautions that the targeted colorectal cancer population has historically been non-responsive to immunotherapy, raising the bar for demonstrating clinical benefit and increasing trial risk.

Cantargia AB News

Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference

Cantargia AB ( ($SE:CANTA) ) has provided an update. Cantargia AB will engage in one-on-one investor and partner...

5d ago

Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference

Cantargia AB ( ($SE:CANTA) ) has provided an announcement. Cantargia AB will participate in TD Cowen’s 46th Annual...

15d ago

Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside

Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB and keeping the price target...

18d ago

Cantargia Highlights Pipeline Progress in 2025 Year-End Report

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia’s year-end report for January to December 2025 outlines...

18d ago

Cantargia Sets Date for 2025 Annual Results and Investor Presentation

An announcement from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia will publish its annual results for...

1M ago

Cantargia to Engage Investors at Leerink Global Healthcare Conference

An update from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia announced that its management team will...

1M ago

Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB

H.C. Wainwright analyst Sara Nik has reiterated their bullish stance on 7V3 stock, giving a Buy rating on...

2M ago

Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer

Cantargia AB ( ($SE:CANTA) ) just unveiled an announcement. Cantargia AB has announced that the first patient has...

2M ago

Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback

H.C. Wainwright analyst Sara Nik reiterated a Buy rating on Cantargia AB today and set a price target...

3M ago

Cantargia Reports TRIFOUR Study Results on Nadunolimab

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia AB announced that the TRIFOUR study, evaluating nadunolimab...

3M ago

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?

Cantargia AB lowest stock price was kr1.00 and its highest was kr6.59 in the past 12 months.

What is Cantargia AB’s market cap?

Cantargia AB’s market cap is kr986.99M.

When is Cantargia AB’s upcoming earnings report date?

Cantargia AB’s upcoming earnings report date is May 26, 2026 which is in 77 days.

How were Cantargia AB’s earnings last quarter?

Cantargia AB released its earnings results on Feb 20, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.19 by kr0.06.

Is Cantargia AB overvalued?

According to Wall Street analysts Cantargia AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cantargia AB pay dividends?

Cantargia AB does not currently pay dividends.

What is Cantargia AB’s EPS estimate?

Cantargia AB’s EPS estimate is -0.18.

How many shares outstanding does Cantargia AB have?

Cantargia AB has 248,611,650 shares outstanding.

What happened to Cantargia AB’s price movement after its last earnings report?

Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.19. Following the earnings report the stock price went down -11.485%.

Which hedge fund is a major shareholder of Cantargia AB?

Currently, no hedge funds are holding shares in SE:CANTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cantargia AB

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

Cantargia AB (CANTA) Earnings & Revenues

Historic Earnings Reports

CANTA Stock 12 Month Forecast

Average Price Target

kr13.99

▲(241.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","7":"kr7","14":"kr14","3.5":"kr3.5","10.5":"kr10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.96711790313392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr13.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.9855660391,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr13.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.96711790313392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr13.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.49,6.142085992548763,6.794171985097526,7.446257977646289,8.098343970195053,8.750429962743816,9.402515955292579,10.054601947841341,10.706687940390104,11.358773932938867,12.01085992548763,12.662945918036392,13.315031910585155,{"y":13.96711790313392,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.49,6.14350507993077,6.7970101598615384,7.450515239792308,8.104020319723077,8.757525399653847,9.411030479584616,10.064535559515384,10.718040639446155,11.371545719376924,12.025050799307692,12.678555879238463,13.332060959169231,{"y":13.9855660391,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.49,6.142085992548763,6.794171985097526,7.446257977646289,8.098343970195053,8.750429962743816,9.402515955292579,10.054601947841341,10.706687940390104,11.358773932938867,12.01085992548763,12.662945918036392,13.315031910585155,{"y":13.96711790313392,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.719,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.43,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.272,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.406,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.235,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.63,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.225,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.185,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >